Evidence map›Paper›PMID 32725403›Full record

SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021

Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis.

Xiangjie Leng, Meirong Shi, Xinyu Liu, Jingzhe Cui, Huaping Sun, Xuejing Lu

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05577910 nacompletednot on this mapstarted 2022, after this paper: background citation

Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress (VIEW) Therapies for Meibomian Gland Dysfunction- A Randomized, Assessor-masked, Active-controlled Clinical Trial

TypeinterventionalSponsorChinese University of Hong KongRan2022 to 2025Enrolled374ConditionsMeibomian Gland DysfunctionArmsVectored thermal pulsation (VTP) therapy, Intense pulsed light with meibomian gland expression (IPL+MGX) therapy, Eyelid Warm Compress Therapy (EW), Topical eye drops (Hypromellose, 3mg/ml)
NCT05857579 nacompletednot on this mapstarted 2022, after this paper: background citation

Diamond Bur Microblepharoexfoliation Combined With Intense Pulse Light and Meibomian Gland Expression for Evaporative Dry Eye: A Short-term Controlled Study

TypeinterventionalSponsorUniversity of SevilleRan2022 to 2023Enrolled70ConditionsDry Eye DiseaseArmsMicroblepharoexfoliation, Intense pulse light, Meibomian gland expression, Home-based therapy
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xiangjie LengChengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China.
Meirong ShiChengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China.
Xinyu LiuChengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China.
Jingzhe CuiChengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China.
Huaping SunDepartment of Ophthalmology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, 210000, China.
Xuejing LuChengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China. luxuejing@cdutcm.edu.cn.ORCID http://orcid.org/0000-0001-5324-4736
Chengdu University of Traditional Chinese Medicine · CNChengdu University · CNNanjing University of Chinese Medicine · CN

Funding

The Special Planning Task of Sichuan Youth Scientific and Technological Innovation Research Team 2017td0030
6 · The paper itself

Abstract

backgroundIntense pulsed light therapy (IPL) is a new method being used to treat meibomian gland dysfunction (MGD) globally. With an increasing number of studies being published, it is necessary to consider additional factors related to treatment. This review aims to investigate the efficacy and safety of IPL for the treatment of MGD.

methodsThe PubMed, EMBASE, Web of Science, Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and SinoMed databases were searched through February 24, 2020. Randomized clinical trials and cohort studies comparing IPL+ meibomian gland expression (MGX) or IPL alone with control groups were included. The weighted mean difference (WMD) was calculated to analyze the Ocular Surface Disease Index (OSDI) score and Standard Patient Evaluation of Eye Dryness (SPEED) score, and the standard mean difference (SMD) was calculated to analyze the tear breakup time (TBUT). Heterogeneity was quantified by the I

resultsNine studies with a total of 539 patients were included. Eight studies examined TBUT, six examined OSDI scores, and four examined SPEED scores. IPL combined with MGX showed superiority regarding the TBUT (SMD 2.33, 95% CI 1.04-3.61), and OSDI scores (WMD 11.93, 95% CI - 17.10 to - 6.77), with high heterogeneity. The SPEED scores were not significantly different.

conclusionsIPL combined with MGX may be an effective and safe treatment for MGD, but it cannot improve all symptoms. IPL alone is not superior to MGX. The efficacy is also affected by the number and average frequency of treatments. The efficacy of IPL may decrease within 6 months after the last treatment, so it should be considered a long-term adjuvant therapy combined with MGX. When patients receive 3 or 4 treatments (once every 3-4 weeks), a return visit at 6 months after the last treatment is required.

Indexed as

Dry Eye SyndromesIntense Pulsed Light TherapyMeibomian Gland DysfunctionHumansMeibomian GlandsTearsIntense pulsed lightMeibomian gland dysfunctionMeta-analysis

Identifiers

PMID32725403
OpenAlexW3046152428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.